MiroBio is a recently launched biologics company with a mission to treat a range of autoimmune and inflammatory disorders. The company is founded by leading immunologists at the University of Oxford who have spent over 15yrs focussed on understanding the mechanisms which underlie T-cell signalling. The technology is based on an IP portfolio of novel antibodies with the ability to activate inhibitory co-receptors on the surface of immune cells, with a deep mechanistic understanding, MiroBio is able to optimise these antibodies to create immune-modulatory therapies which have shown remarkable efficacy in preclinical models of disease. MiroBio is now building out the team and the platform, looking for strong antibody-development expertise to take the lead compounds to clinical proof-of-concept.
MiroBio is a well-funded spin-out from Oxford University. The company is based in Oxford, retaining close links to the world-class immunology expertise and clinical trial experience within the University.
The Oxford Translational Gastroenterology Unit
The TGU main laboratory is situated in the John Radcliffe hospital. The Unit builds on excellent clinical programmes in inflammatory bowel disease and hepatology as well as cutting edge fundamental science programmes in mucosal immunology.
The Oxford Gastroenterology Unit is acknowledged as one of the premier units for clinical care and research in Europe and has attracted clinical and research fellows from all over the world.
We are searching for an immunologist who has recently completed their PhD and is looking for an opportunity to lead a translational project profiling the cellular composition of autoimmune conditions from primary tissue and the mode of action of MiroBio’s novel therapeutic antibodies.
The candidate will:
The Fellow will be based at a leading Oxford University research laboratory at the TGU and will co-ordinate research activity across three different autoimmune disease areas. The Fellow will also work closely with MiroBio immunologists to understand the common and disparate pathobiology across multiple autoimmune conditions. The Fellow will contribute to the development of a rationale for the treatment of specific patient populations with MiroBio’s antibodies.
This role provides the opportunity to become familiar with state of the art single cell expression profiling approaches and the processes involved in target discovery. The role also allows the development of expertise in the use of human tissue models to dissect the role of therapeutic antibodies in ameliorating complex disease pathobiology.
Role qualification and requirements: